NCT05769023

Brief Summary

Conduct a study of people who use drugs (PWUD) perceptions of and access to COVID-19 vaccines as well as reasons for vaccine hesitancy/barriers

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at below P25 for not_applicable covid19

Timeline
13mo left

Started Jan 2023

Longer than P75 for not_applicable covid19

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress77%
Jan 2023May 2027

Study Start

First participant enrolled

January 1, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 1, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 15, 2023

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2027

Last Updated

May 20, 2026

Status Verified

May 1, 2026

Enrollment Period

3.9 years

First QC Date

March 1, 2023

Last Update Submit

May 19, 2026

Conditions

COVID-19

Outcome Measures

Primary Outcomes (1)

  • Vaccine acceptance as assessed by the Oxford COVID-19 Vaccine Hesitancy Scale

    Vaccine acceptance will be assessed using the Oxford COVID-19 Vaccine Hesitancy Scale, a seven-item scale that measures willingness to receive a COVID-19 vaccine. Scores ranged from 7 to 35, with higher scores indicating greater hesitancy.

    1 month

Study Arms (1)

Experimental

EXPERIMENTAL

behavioral intervention

Behavioral: Intervention test

Interventions

Intervention testBEHAVIORAL

behavioral sessions to promote vaccines

Experimental

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • opioid use in prior 2 weeks

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Johns Hopkins Bloomberg School of Public Health

Baltimore, Maryland, 21205, United States

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Carl Latkin, PhD

    Johns Hopkins Bloomberg School of Public Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Model Details: pilot of an intervention
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 1, 2023

First Posted

March 15, 2023

Study Start

January 1, 2023

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

May 30, 2027

Last Updated

May 20, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will share

one year after study completion

Shared Documents
STUDY PROTOCOL
Time Frame
1 year
Access Criteria
researchers

Locations

US(1)